These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Reinders MK; van Roon EN; Jansen TL; Delsing J; Griep EN; Hoekstra M; van de Laar MA; Brouwers JR Ann Rheum Dis; 2009 Jan; 68(1):51-6. PubMed ID: 18250112 [TBL] [Abstract][Full Text] [Related]
5. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094 [TBL] [Abstract][Full Text] [Related]
6. Treatment of the gout and other forms of crystal-induced arthritis. Rodnan GP Bull Rheum Dis; 1982; 32(5):43-53. PubMed ID: 6762236 [No Abstract] [Full Text] [Related]
8. The current state of care in gout: Addressing the need for better understanding of an ancient disease. Zychowicz ME; Pope RS; Graser E J Am Acad Nurse Pract; 2010 Nov; 22 Suppl 1():623-36. PubMed ID: 21054636 [TBL] [Abstract][Full Text] [Related]
9. Febuxostat versus allopurinol for gout. Gelber AC N Engl J Med; 2006 Apr; 354(14):1532-3; author reply 1532-3. PubMed ID: 16602151 [No Abstract] [Full Text] [Related]
10. Febuxostat for prevention of gout attacks. Pohar S; Murphy G Issues Emerg Health Technol; 2006 Aug; (87):1-4. PubMed ID: 16958189 [TBL] [Abstract][Full Text] [Related]
11. Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid. Hilmi BA; Asmahan MI; Rosman A Med J Malaysia; 2012 Feb; 67(1):125-6. PubMed ID: 22582566 [TBL] [Abstract][Full Text] [Related]
13. Febuxostat: a new treatment for hyperuricaemia in gout. Edwards NL Rheumatology (Oxford); 2009 May; 48 Suppl 2():ii15-ii19. PubMed ID: 19447778 [TBL] [Abstract][Full Text] [Related]
14. Febuxostat (Uloric) for chronic treatment of gout. Med Lett Drugs Ther; 2009 May; 51(1312):37-8. PubMed ID: 19448587 [TBL] [Abstract][Full Text] [Related]
15. Febuxostat efficacy in allopurinol-resistant tophaceous gout. Uh M; Reid G J Clin Rheumatol; 2011 Jun; 17(4):204-6. PubMed ID: 21617552 [TBL] [Abstract][Full Text] [Related]
16. Evaluation and treatment of gout as a chronic disease. Perez-Ruiz F; Herrero-Beites AM Adv Ther; 2012 Nov; 29(11):935-46. PubMed ID: 23104464 [TBL] [Abstract][Full Text] [Related]
17. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369 [TBL] [Abstract][Full Text] [Related]
18. [The use of Allomaron in treating hyperuricemia]. Balkarov IM Ter Arkh; 1994; 66(1):40-2. PubMed ID: 8146793 [No Abstract] [Full Text] [Related]
19. [Hyperuricemia and gout--treatment]. Gröbner W; Walter-Sack I Dtsch Med Wochenschr; 2002 Feb; 127(5):210-3. PubMed ID: 11821994 [No Abstract] [Full Text] [Related]
20. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. Chohan S J Rheumatol; 2011 Sep; 38(9):1957-9. PubMed ID: 21724706 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]